Table 3 Analytical parameters for the SPE-LC-MS/MS and SPE-UHPLC-MS/MS methods
Nº | Compound | RSDa(%) n=6 | LODb(ng/L) | LOQc(ng/L) | Recovery (%) n=6 |
|---|---|---|---|---|---|
1 | Naproxen | 9.6 | 0.6 | 1.8 | 101.8 ± 7.0 |
2 | Carbamazepine | 10.7 | 0.3 | 1.1 | 105.6 ± 4.4 |
3 | Ketoprofen | 9.2 | 2.4 | 7.9 | 98.6 ± 9.4 |
4 | Bezafibrate | 7.8 | 2.9 | 9.6 | 91.6 ± 11.4 |
5 | Atenolol | 6.5 | 7.9 | 26.3 | 67.2 ± 4.4 |
6 | Metamizole | 7.9 | 6.3 | 21.1 | 54.4 ± 4.3 |
7 | Paraxanthine | 10.8 | 2.2 | 7.8 | 96.4 ± 10.4 |
8 | Fluoxetine | 7.7 | 97.4 | 324.7 | 21.0 ± 1.6 |
9 | Levofloxacin | 8.5 | 9.1 | 30.3 | 82.4 ± 14.0 |
10 | Norfloxacin | 8.5 | 8.5 | 28.0 | 85.3 ± 5.2 |
11 | Ciprofloxacin | 6.8 | 8.6 | 28.7 | 86.2 ± 2.1 |
12 | Enrofloxacin | 7.0 | 5.3 | 17.7 | 94.0 ± 6.1 |
13 | Sarafloxacin | 9.8 | 11.1 | 37.0 | 86.1 ± 11.2 |